Dianthus reveals preclinical data for its Phase II neuromuscular candidate
01 Jul 2024
Phase 2Clinical ResultDrug ApprovalVaccine
Preview
Source: Pharmaceutical Technology
Myasthenia gravis and chronic demyelinating polyneuropathy can both cause weakness of certain muscles. Credit: Toa55 via Shutterstock.
Clinical-stage biotech firm Dianthus Therapeutics has shared preclinical data of its investigational agent DNTH103 being tested in in vitro models of generalised myasthenia gravis (gMG) and chronic demyelinating polyneuropathy (CIDP).
Data from the blood of three patients with gMG showed that DNTH103 reached a 24.8% – 27.8% reduction from baseline in the fatigue index, which measures improvements in neurotransmission and muscle contraction. Myasthenia gravis is an autoimmune disorder that causes muscle weakness and fatigue due to disrupted communication between nerves and muscles.
A second dataset looked at the blood of patients with CIDP, showing that the highest dose of DNTH103 used restored levels of neuronal conduction velocity. CIDP is a neurological disorder characterised by progressive weakness and impaired sensory function in the legs and arms due to inflammation of the peripheral nerves.
The preclinical data, presented at the European Academy of Neurology (EAN) 2024 Congress in Helsinki, Finland, also showed that DNTH103 has the potential to be formulated as a patient-friendly, infrequent, subcutaneous (SC) self-administration.
DNTH103 is a fully human IgG4 monoclonal antibody that inhibits the active form of C1s, a protein involved in a pathway that promotes inflammation. This pathway, known as the classical complement system, typically functions to clear microbes and damaged cells but is also suggested to play a role in some autoimmune diseases.
See Also:Valneva’s chikungunya vaccine gains EC’s market authorisation
Preview
Source: Pharmaceutical Technology
UK’s antibiotic subscription funding model – a route to market sustainability?
Preview
Source: Pharmaceutical Technology
This data supports Dianthus’s recently initiated Phase II study. The MaGic trial (NCT06282159) – which will enrol 60 gMG patients who are anti-acetylcholine receptor (AChR) antibody-positive – was initiated in February 2024. Patients will receive DNTH103 via SC injection every two weeks, with topline data expected in H2 2025.
Last month, the company received the green light from the US Food and Drug Administration (FDA) to begin a Phase II trial of DNTH103 to treat multifocal motor neuropathy (MMN). Initial topline results are set for H2 2026, with Dianthus planning another Phase II CIDP study of the drug in H2 2024.
In October 2023, UCB’s ZILBRYSQ (zilucoplan) was approved by the FDA for the treatment of adults with gMG who are AChR antibody positive. The drug is a targeted peptide inhibitor of complement component 5 (C5). However, C5 inhibitorsC5 inhibitors have an increased risk for serious bacterial infection, says Dianthus’ CEO Marino Garcia.
“We aim to demonstrate that DNTH103 may become a best-in-class classical complement pathway inhibitor with infrequent self-administration that provides effective and consistent control of symptoms for people living with neuromuscular conditions, without inhibiting the alternative and lectin pathways that are critical in the defence against infection,” added Garcia.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.